Tobacco use remains one of the most important preventable causes of disease and premature death in the United States, even though cigarette smoking has fallen substantially over several decades. The current pattern is more complicated than a simple decline in smoking because the nicotine market now includes cigarettes, e-cigarettes, cigars, smokeless tobacco, nicotine pouches, hookah, and other products. These products differ in toxic exposure, but none should be treated as harmless, particularly for young people, pregnant individuals, or people who do not already use nicotine.
The most recent National Health Interview Survey early-release data report that 9.1 percent of U.S. adults currently smoked cigarettes in 2025, while 6.7 percent currently used electronic cigarettes. Cigarette smoking is therefore at a historically low level, but CDC analysis shows that the decline in exclusive cigarette smoking since 2017 has been offset partly by growth in exclusive e-cigarette use. Tobacco control must now address both the continued lethality of combustible products and the changing forms of nicotine use (CDC, 2025a; NCHS, 2026).
Health Burden
Combustible cigarette smoking remains the largest source of tobacco-related mortality. CDC reported in July 2026 that cigarette smoking and secondhand smoke exposure cause more than 480,000 deaths each year in the United States. More than 16 million Americans are living with at least one disease caused by smoking. These figures show why cigarette use remains a population-health issue rather than only an individual behavior (CDC, 2026a).
Tobacco smoke contains thousands of chemicals, including carcinogens, cardiovascular toxins, and substances that damage lung tissue. Smoking causes cancers in multiple organs, contributes to coronary heart disease and stroke, and is a major cause of chronic obstructive pulmonary disease. The risks increase with cumulative exposure, but there is no safe level of cigarette smoking. Even low-intensity smoking can raise cardiovascular risk substantially.
Secondhand smoke extends the burden to people who do not smoke. Exposure increases the risk of cardiovascular and respiratory disease in adults and can harm infants and children. Smoke-free workplaces, restaurants, public buildings, and shared housing environments therefore have a protective function independent of whether smokers themselves intend to quit.
Pregnancy is another high-risk context. Tobacco smoke and nicotine exposure can affect fetal growth and pregnancy outcomes. Cessation support should be offered without stigma because shame can make patients less willing to disclose use or seek help. Smoke-free homes and vehicles are especially important after birth because infants cannot control their exposure.
Other combustible products also carry important risks. Cigars produce many of the same toxic substances as cigarettes, while hookah smoke is not made safe by passing through water. Long sessions can involve substantial smoke exposure. Tobacco consumption should therefore be assessed by product type, frequency, intensity, and concurrent use rather than by cigarettes alone.
Electronic cigarettes require a different risk discussion. They generate aerosol rather than tobacco smoke and generally expose users to a different toxicant profile than combustible cigarettes. This does not make them harmless. Many products deliver nicotine efficiently, and aerosol can contain ultrafine particles, flavoring chemicals, metals, and other substances. For an adult who currently smokes, completely replacing cigarettes may reduce exposure to many combustion-related toxicants, but dual use can preserve significant smoking-related risk. People who do not use tobacco or nicotine should not start vaping.
Changing Use
Adult tobacco use has changed substantially. CDC’s 2025 analysis of national survey data found that cigarette smoking reached its lowest level in roughly six decades, while exclusive e-cigarette use increased enough to offset much of the reduction in the number of adults exclusively smoking cigarettes between 2017 and 2023. This shift means that evaluating progress through cigarette prevalence alone can miss changes in the wider tobacco market (Arrazola et al., 2025).
The latest 2025 NHIS estimate of 9.1 percent adult cigarette smoking is encouraging, but prevalence is not evenly distributed. Tobacco use remains associated with socioeconomic disadvantage, rural residence, disability, psychological distress, limited insurance coverage, and other structural conditions. Earlier national analyses also found elevated prevalence among some sexual-minority populations and groups with lower educational attainment. These differences reflect a combination of marketing exposure, stress, treatment access, social environment, and economic conditions rather than one individual trait.
Youth use has also changed. FDA’s analysis of the 2025 National Youth Tobacco Survey, published in June 2026, reported that 7.2 percent of U.S. middle and high school students—about 2.01 million students—currently used at least one tobacco product. E-cigarettes remained the most commonly used product at 5.2 percent, followed by nicotine pouches at 1.7 percent and cigarettes at 1.4 percent. Overall youth tobacco use declined between 2022 and 2025, but millions of students still report recent nicotine or tobacco exposure (FDA, 2026).
These trends matter because most tobacco use begins before or during young adulthood. Nicotine can create dependence, and flavored products can increase appeal. Regulation and prevention therefore need to consider product design, marketing, retail access, social media, price, and peer influence rather than relying only on classroom education.
Product substitution also complicates interpretation. A decline in smoking can improve health even if some former smokers switch to lower-exposure products, but population benefit is reduced when new users who otherwise would not have used nicotine begin vaping or using pouches. Surveillance should therefore distinguish initiation, switching, dual use, complete cessation, and long-term patterns.
The shift in smoking prevalence also means cessation services need to reach populations where smoking is becoming more concentrated. As overall prevalence falls, remaining users may include more people with high dependence, mental-health conditions, unstable housing, or repeated unsuccessful quit attempts. Generic campaigns may become less effective unless they are paired with accessible treatment.
Control Strategies
The ecological model remains a useful framework for tobacco control because nicotine use is shaped by more than individual motivation. Downstream interventions support individuals through counseling and medication. Midstream interventions change organizations and communities through smoke-free workplaces, healthcare protocols, school policies, and local programs. Upstream interventions alter price, product standards, advertising, retail access, and the broader commercial environment.
Clinical cessation support is one of the most important individual-level interventions. Evidence-based treatment can include behavioral counseling and approved cessation medications selected according to patient preference and clinical circumstances. Repeated quit attempts are common and should not be treated as evidence of weak character. Nicotine dependence is a chronic, relapsing condition for many users, and supportive follow-up can improve the likelihood of long-term abstinence.
Price and tax policy can reduce cigarette consumption and initiation, particularly among price-sensitive young people. However, tobacco taxes can also be financially regressive for low-income smokers who remain dependent. Equity-oriented policy should therefore use revenue to support cessation, prevention, and healthcare rather than relying only on higher prices.
Smoke-free environments protect non-smokers while also changing social norms and reducing cues for smoking. Comprehensive policies are generally easier to understand than rules with many exceptions. Shared housing requires special attention because smoke can move between units, although enforcement should avoid approaches that simply displace vulnerable residents without providing cessation support.
Mass-media and counter-marketing campaigns can increase awareness, challenge industry messaging, and direct people toward treatment. Fear-based messages can be effective in some contexts, but they should be paired with clear action and should avoid stigmatizing people who are dependent. The objective is to reduce tobacco use, not to shame users.
Healthcare systems can strengthen cessation by recording tobacco use, offering treatment during routine care and hospitalization, linking patients with quitlines or digital services, and following up after discharge. Mental-health and substance-use services are particularly important because smoking prevalence has historically been high among people receiving these services.
Regulation must also adapt to the current market. Policies designed only for cigarettes can leave gaps for disposable e-cigarettes, nicotine pouches, flavored products, and new delivery systems. Product standards, age restrictions, advertising rules, warning labels, and enforcement should be updated as products evolve.
California and Equity
California remains an important example because its tobacco-control program combined taxation, smoke-free policies, public communication, community activity, and cessation support rather than relying on one intervention. Research by Lightwood and Glantz linked the program with reductions in cigarette consumption, smoking prevalence, and healthcare costs between 1989 and 2008. Although observational evaluations cannot attribute every change to one program component, the case supports the broader ecological approach.
The California experience also shows that success can create a new challenge. When average smoking prevalence declines, tobacco use may become increasingly concentrated among groups facing poverty, mental-health challenges, discrimination, unstable housing, occupational stress, or targeted marketing. A program can improve statewide averages while leaving large disparities behind.
Equity therefore requires more than offering the same intervention to everyone. Rural residents may need telehealth or mobile cessation services. People with serious mental illness may benefit from treatment integrated into psychiatric care. People with low income may need free or low-cost medication. Multilingual communities need culturally and linguistically appropriate services. Data should be detailed enough to identify populations hidden inside broad averages.
Commercial determinants of health also deserve attention. Tobacco and nicotine companies influence product design, distribution, pricing, advertising, and lobbying. Public-health programs should evaluate how these commercial strategies affect youth initiation and adult cessation rather than framing tobacco use entirely as personal choice.
The future of U.S. tobacco control should therefore focus on two goals simultaneously: eliminating combustible tobacco use as rapidly as possible and preventing a new generation from becoming dependent on nicotine through emerging products. Success should be measured through smoking prevalence, total tobacco use, successful cessation, youth initiation, secondhand exposure, disease burden, and disparities.
The national picture is encouraging but unfinished. Adult cigarette smoking fell to 9.1 percent in 2025, and youth tobacco use continued to decline, yet smoking and secondhand exposure still cause more than 480,000 U.S. deaths annually. The most effective response remains a layered one: accessible cessation treatment, smoke-free environments, taxation, regulation, accurate risk communication, surveillance of new products, and focused support for populations carrying the greatest burden.
References
Arrazola, R. A., Husten, C. G., Cornelius, M. E., & Armour, B. S. (2025). Tobacco product use among adults—United States, 2017–2023. Morbidity and Mortality Weekly Report, 74(7), 118–121.
Centers for Disease Control and Prevention. (2026a). Facts About Cigarette Smoking and Radiation.
Centers for Disease Control and Prevention. (2025). Cigarette smoking.
Centers for Disease Control and Prevention. (2024). Cigarettes and cancer.
Centers for Disease Control and Prevention. (2024). Cigarettes and cardiovascular disease.
Centers for Disease Control and Prevention. (2024). Cigarettes and COPD.
Food and Drug Administration. (2026). Results from the 2025 National Youth Tobacco Survey.
National Center for Health Statistics. (2026). FastStats: Cigarette Smoking and Electronic Cigarette Use.
Lightwood, J., & Glantz, S. A. (2013). The effect of the California Tobacco Control Program on smoking prevalence, cigarette consumption, and healthcare costs: 1989–2008. PLoS ONE, 8(2), e47145. https://doi.org/10.1371/journal.pone.0047145
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
